BBP vs SBIO

Both BBP and SBIO are ETFs. BBP has a lower 5-year return than SBIO (1.48% vs 2.15%). BBP has a higher expense ratio than SBIO (0.79% vs 0.5%). Below is the comparison between BBP and SBIO.

BBP SBIO
Security Type ETF ETF
Segment Equity: U.S. Biotech Equity: U.S. Biotech
Family Virtus ALPS
Net Assets $13.50M $108.40M
Expense Ratio 0.79% 0.50%
Management Style passive (index-based) passive (index-based)
Dividend Yield 0.00% 0.00%
Underlying Index LifeSci Biotechnology Products Index Poliwogg Medical Breakthroughs Index
YTD Return -20.92% -37.51%
1-Year Return -25.26% -43.65%
3-Year Return -0.99% -7.86%
5-Year Return 1.48% 2.15%
10-Year Return 0.00% 0.00%

BBP

BBP description

The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. The Index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering or product candidate.

BBP performance & returns

YTD Return -20.92%
1-Month Return -3.39%
3-Month Return -8.42%
1-Year Return -25.26%
3-Year Return -0.99%
5-Year Return 1.48%
10-Year Return 0.00%
BBP expense ratio is 0.79%.

BBP holdings

Top 10 Holdings (34.61% of Total Assets)

Name Symbol % Assets
Sage Therapeutics Inc SAGE 4.86%
BeiGene Ltd ADR BGNE 4.34%
Amicus Therapeutics Inc FOLD 3.91%
Ultragenyx Pharmaceutical Inc RARE 3.54%
Blueprint Medicines Corp BPMC 3.51%
Retrophin Inc RTRX 3.17%
Halozyme Therapeutics Inc HALO 2.94%
Insmed Inc INSM 2.90%
United Therapeutics Corp UTHR 2.79%
Seagen Inc Ordinary Shares SGEN 2.65%

BBP pros

None that we could think of.

BBP cons

None that we could think of.

Other relevant BBP comparisons

You may also want to check out the following BBP comparisons that investors often look for on Finny

Or use Finny's Comparison Tool to create a comparison you'd like to see.

SBIO

SBIO description

The Fund seeks investment results that correspond generally to the performance of index, the Poliwogg Medical Breakthroughs. The Index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration.

SBIO performance & returns

YTD Return -37.51%
1-Month Return -9.72%
3-Month Return -20.81%
1-Year Return -43.65%
3-Year Return -7.86%
5-Year Return 2.15%
10-Year Return 0.00%
SBIO expense ratio is 0.5%.

SBIO holdings

Top 10 Holdings (38.41% of Total Assets)

Name Symbol % Assets
Mirati Therapeutics Inc MRTX 6.66%
Acceleron Pharma Inc XLRN 4.31%
United Therapeutics Corp UTHR 4.10%
Arrowhead Pharmaceuticals Inc ARWR 4.03%
Blueprint Medicines Corp BPMC 3.89%
Arena Pharmaceuticals Inc ARNA 3.40%
Emergent BioSolutions Inc EBS 3.28%
Allakos Inc ALLK 3.20%
Kodiak Sciences Inc KOD 2.79%
Vir Biotechnology Inc VIR 2.75%

SBIO pros

None that we could think of.

SBIO cons

The following are SBIO weaknesses from our perspective:

  • SBIO net assets are $108.40 million. This fund is not a popular choice with retail investors.
  • SBIO 3-year return is -6.63%, which is lower than the 3-year return of the benchmark index (MSCI ACWI NR USD), 9.04%.
  • SBIO 5-year return is 2.15%, which is lower than the 5-year return of the benchmark index (MSCI ACWI NR USD), 8.14%.

Other relevant SBIO comparisons

You may also want to check out the following SBIO comparisons that investors often look for on Finny

Or use Finny's Comparison Tool to create a comparison you'd like to see.
You can check out all comparisons Finny users have looked for here. Feel free to the browse the list and view the comparisons that are of an interest to you.